抗体受託製造の世界市場、規模、シェア、動向、産業分析レポート：製品別、由来別、治療領域別、エンドユーザー別、地域別 - 市場予測、2025年～2034年

Polaris Market Research社の最新調査によると、抗体受託製造市場規模は2034年までに449億6,000万米ドルに達する見込みです。本レポートでは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

抗体受託製造は、モノクローナル抗体、ポリクローナル抗体、二重特異性抗体の製造を外部に委託することで、バイオ製薬企業が増大する治療や診断の需要に対応できるようにするものです。これらのサービスは、高収率、製品の一貫性、臨床グレードの安全性を確保するため、厳格な規制・品質ガイドラインの下で実施されます。

市場成長の原動力となっているのは、がんやその他の慢性疾患の世界の罹患率の増加であり、これが抗体ベースの標的治療に対する需要を牽引しています。腫瘍学と免疫学における世界の研究開発費の増加は、次世代生物製剤の開発をさらに後押ししています。

抗体受託製造市場レポートハイライト

製品別では、長期免疫抑制療法を必要とする腎臓、肝臓、心臓移植手術件数の増加により、モノクローナル抗体セグメントが2024年に最大の市場シェアを占めました。

由来別では、複雑なタンパク質構造への高い適合性と治療効果に不可欠なグリコシル化プロファイルを作り出す能力により、哺乳類セグメントが市場を独占しました。

治療領域別では、新興ウイルス感染症や慢性感染症の流行に対抗するための抗体ベースの治療に対する需要の高まりに後押しされ、感染症セグメントが最も急速な成長が見込まれています。

エンドユーザー別では、コスト最適化と迅速な商業化のために抗体製造を専門CMOに委託する傾向が強まっていることから、2024年にはバイオ製薬企業セグメントが圧倒的なシェアを占めています。

北米は、堅調なバイオ医薬品製造能力と生産プロセスへの高度な生物製剤の急速な統合に後押しされ、2024年に世界の抗体受託製造市場を独占しました。

アジア太平洋地域は、バイオテクノロジー産業の著しい成長に加え、国際的な製薬企業との提携やアウトソーシング契約の増加により、着実な成長を遂げました。

世界の主要市場プレーヤーには、Lonza Group AG、Samsung Biologics、WuXi Biologics、Boehringer Ingelheim International GmbH、Fujifilm Diosynth Biotechnologies、Catalent, Inc.、AbbVie Inc.、Thermo Fisher Scientific Inc.、Shilpa Medicare Ltd.、Lotte Biologics、Merck Group、Charles River Laboratoriesなどがあります。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の抗体受託製造市場の洞察

• 市場スナップショット
• 抗体受託製造市場力学
  • 促進要因と機会
    • 世界中でがんの症例が増加
    • 世界の研究開発費の増加
  • 抑制要因と課題
    • 高い製造コストと複雑な規制遵守
• PESTEL分析
• 抗体受託製造市場の動向
• バリューチェーン分析

第5章 世界の抗体受託製造市場：製品別

• 主な調査結果
• イントロダクション
• モノクローナル抗体
• ポリクローナル抗体
• 二重特異性抗体
• その他

第6章 世界の抗体受託製造市場：由来別

• 主な調査結果
• イントロダクション
• 哺乳類
• 微生物

第7章 世界の抗体受託製造市場：治療領域別

• 主な調査結果
• イントロダクション
• 腫瘍学
• 神経学
• 心臓病学
• 感染症
• その他

第8章 世界の抗体受託製造市場：エンドユーザー別

• 主な調査結果
• イントロダクション
• バイオ医薬品企業
• 研究所
• その他

第9章 世界の抗体受託製造市場：地域別

• 主な調査結果
• イントロダクション
  • 抗体受託製造市場評価：地域別、2020-2034年
• 北米
  • 北米：製品別、2020～2034年
  • 北米：由来別、2020～2034年
  • 北米：治療領域別、2020～2034年
  • 北米：エンドユーザー別、2020～2034年
  • 米国
  • カナダ
• 欧州
  • 欧州：製品別、2020～2034年
  • 欧州：由来別、2020～2034年
  • 欧州：治療領域別、2020～2034年
  • 欧州：エンドユーザー別、2020～2034年
  • 英国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • オランダ
  • ロシア
  • その他欧州
• アジア太平洋地域
  • アジア太平洋地域：製品別、2020～2034年
  • アジア太平洋地域：由来別、2020～2034年
  • アジア太平洋地域：治療領域別、2020年～2034年
  • アジア太平洋地域：エンドユーザー別、2020～2034年
  • 中国
  • インド
  • マレーシア
  • 日本
  • インドネシア
  • 韓国
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ
  • 中東・アフリカ：製品別、2020～2034年
  • 中東・アフリカ：由来別、2020～2034年
  • 中東・アフリカ：治療領域別、2020～2034年
  • 中東・アフリカ：エンドユーザー別、2020～2034年
  • サウジアラビア
  • アラブ首長国連邦
  • イスラエル
  • 南アフリカ
  • その他中東・アフリカ
• ラテンアメリカ
  • ラテンアメリカ：製品別、2020～2034年
  • ラテンアメリカ：由来別、2020～2034年
  • ラテンアメリカ：治療領域別、2020-2034年
  • ラテンアメリカ：エンドユーザー別、2020～2034年
  • メキシコ
  • ブラジル
  • アルゼンチン
  • その他ラテンアメリカ

第10章 競合情勢

• 拡大と買収の分析
  • 拡大
  • 買収
• 提携/協業/合意/公開

第11章 企業プロファイル

• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• Catalent, Inc.
• Charles River Laboratories
• Fujifilm Diosynth Biotechnologies
• Lonza Group AG
• Lotte Biologics
• Merck Group
• Samsung Biologics
• Shilpa Medicare Ltd.
• Thermo Fisher Scientific Inc.
• WuXi Biologics

List of Tables:

• Table 1 Global Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 2 Global Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 3 Global Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 4 Global Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 5 North America: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 6 North America: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 7 North America: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 8 North America: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 9 U.S.: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 10 U.S.: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 11 U.S.: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 12 U.S.: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 13 Canada: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 14 Canada: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 15 Canada: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 16 Canada: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 17 Europe: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 18 Europe: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 19 Europe: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 20 Europe: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 21 UK: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 22 UK: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 23 UK: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 24 UK: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 25 France: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 26 France: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 27 France: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 28 France: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 29 Germany: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 30 Germany: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 31 Germany: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 32 Germany: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 33 Italy: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 34 Italy: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 35 Italy: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 36 Italy: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 37 Spain: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 38 Spain: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 39 Spain: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 40 Spain: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 41 Netherlands: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 42 Netherlands: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 43 Netherlands: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 44 Netherlands: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 45 Russia: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 46 Russia: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 47 Russia: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 48 Russia: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 49 Rest of Europe: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 50 Rest of Europe: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 51 Rest of Europe: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 52 Rest of Europe: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 53 Asia Pacific: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 54 Asia Pacific: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 55 Asia Pacific: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 56 Asia Pacific: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 57 China: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 58 China: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 59 China: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 60 China: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 61 India: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 62 India: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 63 India: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 64 India: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 65 Malaysia: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 66 Malaysia: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 67 Malaysia: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 68 Malaysia: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 69 Japan: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 70 Japan: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 71 Japan: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 72 Japan: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 73 Indonesia: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 74 Indonesia: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 75 Indonesia: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 76 Indonesia: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 77 South Korea: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 78 South Korea: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 79 South Korea: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 80 South Korea: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 81 Australia: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 82 Australia: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 83 Australia: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 84 Australia: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 85 Rest of Asia Pacific: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 86 Rest of Asia Pacific: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 87 Rest of Asia Pacific: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 88 Rest of Asia Pacific: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 89 Middle East & Africa: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 90 Middle East & Africa: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 91 Middle East & Africa: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 92 Middle East & Africa: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 93 Saudi Arabia: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 94 Saudi Arabia: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 95 Saudi Arabia: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 96 Saudi Arabia: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 97 UAE: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 98 UAE: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 99 UAE: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 100 UAE: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 101 Israel: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 102 Israel: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 103 Israel: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 104 Israel: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 105 South Africa: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 106 South Africa: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 107 South Africa: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 108 South Africa: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 109 Rest of Middle East & Africa: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 110 Rest of Middle East & Africa: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 111 Rest of Middle East & Africa: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 112 Rest of Middle East & Africa: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 113 Latin America: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 114 Latin America: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 115 Latin America: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 116 Latin America: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 117 Mexico: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 118 Mexico: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 119 Mexico: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 120 Mexico: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 121 Brazil: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 122 Brazil: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 123 Brazil: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 124 Brazil: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 125 Argentina: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 126 Argentina: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 127 Argentina: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 128 Argentina: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• Table 129 Rest of Latin America: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• Table 130 Rest of Latin America: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• Table 131 Rest of Latin America: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• Table 132 Rest of Latin America: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)

List of Figures:

• Figure 1. Global Antibody Contract Manufacturing Market, 2020-2034 (USD Billion)
• Figure 2. Integrated Ecosystem
• Figure 3. Research Methodology: Top-Down & Bottom-Up Price
• Figure 4. Market by Geography
• Figure 5. Porter's Five Forces
• Figure 6. Market by Product
• Figure 7. Global Antibody Contract Manufacturing Market, by Product, 2024 & 2034 (USD Billion)
• Figure 8. Market by Source
• Figure 9. Global Antibody Contract Manufacturing Market, by Source, 2024 & 2034 (USD Billion)
• Figure 10. Market by Therapeutic Area
• Figure 11. Global Antibody Contract Manufacturing Market, by Therapeutic Area, 2024 & 2034 (USD Billion)
• Figure 12. Market by End User
• Figure 13. Global Antibody Contract Manufacturing Market, by End User, 2024 & 2034 (USD Billion)

The antibody contract manufacturing market size is expected to reach USD 44.96 billion by 2034, according to a new study by Polaris Market Research. The report "Antibody Contract Manufacturing Market Share, Size, Trends, Industry Analysis Report: By Product (Monoclonal Antibodies, Polyclonal Antibodies, Bispecific Antibodies, Others), By Source, By Therapeutic Area, By End User, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Antibody contract manufacturing involves the outsourced production of monoclonal antibodies, polyclonal, and bispecific antibodies, enabling biopharmaceutical companies to meet growing therapeutic and diagnostic demands. These services are executed under stringent regulatory and quality guidelines to ensure high yield, product consistency and clinical-grade safety.

The market growth is fueled by the increasing global incidence of cancer and other chronic diseases, which is driving demand for targeted antibody-based therapies. Rising global R&D expenditure in oncology and immunology is further boosting the development of next-generation biologics.

Antibody Contract Manufacturing Market Report Highlights

Based on product, the monoclonal antibodies segment accounted for the largest market share in 2024, due to the rising number of kidney, liver, and heart transplant surgeries requiring long-term immunosuppressive therapy.

Based on source, the mammalian segment dominated the market, driven by its high compatibility with complex protein structures and ability to produce glycosylation profiles essential for therapeutic efficacy.

Based on therapeutic area, the infectious diseases segment is expected to witness the fastest growth, fueled by increasing demand for antibody-based therapies to combat emerging viral infections and rising prevalence of chronic infectious conditions.

Based on end user, the biopharmaceutical companies segment held the dominant share in 2024, due to the growing trend of outsourcing antibody production to specialized CMOs for cost optimization and faster commercialization.

North America dominated the global antibody contract manufacturing market in 2024, fueled by robust biopharmaceutical manufacturing capacity and the rapid integration of advanced biologics into production processes.

Asia Pacific witnessed a steady growth, due to significant growth in the regional biotechnology industry, coupled with rising collaborations and outsourcing agreements with international pharmaceutical companies.

A few global key market players include Lonza Group AG, Samsung Biologics, WuXi Biologics, Boehringer Ingelheim International GmbH, Fujifilm Diosynth Biotechnologies, Catalent, Inc., AbbVie Inc., Thermo Fisher Scientific Inc., Shilpa Medicare Ltd., Lotte Biologics, Merck Group, and Charles River Laboratories.

Polaris Market Research has segmented the market report on the basis of product, source, therapeutic area, end user, and region:

By Product Outlook (Revenue, USD Billion, 2020-2034)

Monoclonal Antibodies

Polyclonal Antibodies

Bispecific Antibodies

Others

By Source Outlook (Revenue, USD Billion, 2020-2034)

Mammalian

Microbial

By Therapeutic Area (Revenue, USD Billion, 2020-2034)

Oncology

Neurology

Cardiology

Infectious Diseases

Other Therapeutic Areas

By End User (Revenue, USD Billion, 2020-2034)

Biopharmaceutical Companies

Research Laboratories

Others

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Antibody Contract Manufacturing Market Insights

• 4.1. Antibody Contract Manufacturing Market - Market Snapshot
• 4.2. Antibody Contract Manufacturing Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Increasing Cases of Cancer Worldwide
    • 4.2.1.2. Rising Global R&D Expenditure
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. High Manufacturing Cost and Complex Regulatory Compliance
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTEL Analysis
• 4.5. Antibody Contract Manufacturing Market Trends
• 4.6. Value Chain Analysis

5. Global Antibody Contract Manufacturing Market, by Product

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
• 5.3. Monoclonal Antibodies
  • 5.3.1. Global Antibody Contract Manufacturing Market, by Monoclonal Antibodies, by Region, 2020-2034 (USD Billion)
• 5.4. Polyclonal Antibodies
  • 5.4.1. Global Antibody Contract Manufacturing Market, by Polyclonal Antibodies, by Region, 2020-2034 (USD Billion)
• 5.5. Bispecific Antibodies
  • 5.5.1. Global Antibody Contract Manufacturing Market, by Bispecific Antibodies, by Region, 2020-2034 (USD Billion)
• 5.6. Others
  • 5.6.1. Global Antibody Contract Manufacturing Market, by Others, by Region, 2020-2034 (USD Billion)

6. Global Antibody Contract Manufacturing Market, by Source

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
• 6.3. Mammalian
  • 6.3.1. Global Antibody Contract Manufacturing Market, by Mammalian, by Region, 2020-2034 (USD Billion)
• 6.4. Microbial
  • 6.4.1. Global Antibody Contract Manufacturing Market, by Microbial, by Region, 2020-2034 (USD Billion)

7. Global Antibody Contract Manufacturing Market, by Therapeutic Area

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
• 7.3. Oncology
  • 7.3.1. Global Antibody Contract Manufacturing Market, by Oncology, by Region, 2020-2034 (USD Billion)
• 7.4. Neurology
  • 7.4.1. Global Antibody Contract Manufacturing Market, by Neurology, by Region, 2020-2034 (USD Billion)
• 7.5. Cardiology
  • 7.5.1. Global Antibody Contract Manufacturing Market, by Cardiology, by Region, 2020-2034 (USD Billion)
• 7.6. Infectious Diseases
  • 7.6.1. Global Antibody Contract Manufacturing Market, by Infectious Diseases, by Region, 2020-2034 (USD Billion)
• 7.7. Other Therapeutic Areas
  • 7.7.1. Global Antibody Contract Manufacturing Market, by Other Therapeutic Areas, by Region, 2020-2034 (USD Billion)

8. Global Antibody Contract Manufacturing Market, by End User

• 8.1. Key Findings
• 8.2. Introduction
  • 8.2.1. Global Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• 8.3. Biopharmaceutical Companies
  • 8.3.1. Global Antibody Contract Manufacturing Market, by Biopharmaceutical Companies by Region, 2020-2034 (USD Billion)
• 8.4. Research Laboratories
  • 8.4.1. Global Antibody Contract Manufacturing Market, by Research Laboratories, by Region, 2020-2034 (USD Billion)
• 8.5. Others
  • 8.5.1. Global Antibody Contract Manufacturing Market, by Others, by Region, 2020-2034 (USD Billion)

9. Global Antibody Contract Manufacturing Market, by Geography

• 9.1. Key Findings
• 9.2. Introduction
  • 9.2.1. Antibody Contract Manufacturing Market Assessment, By Geography, 2020-2034 (USD Billion)
• 9.3. Antibody Contract Manufacturing Market - North America
  • 9.3.1. North America: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
  • 9.3.2. North America: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
  • 9.3.3. North America: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
  • 9.3.4. North America: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.3.5. Antibody Contract Manufacturing Market - U.S.
    • 9.3.5.1. U.S.: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.3.5.2. U.S.: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.3.5.3. U.S.: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.3.5.4. U.S.: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.3.6. Antibody Contract Manufacturing Market - Canada
    • 9.3.6.1. Canada: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.3.6.2. Canada: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.3.6.3. Canada: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.3.6.4. Canada: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• 9.4. Antibody Contract Manufacturing Market - Europe
  • 9.4.1. Europe: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
  • 9.4.2. Europe: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
  • 9.4.3. Europe: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
  • 9.4.4. Europe: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.4.5. Antibody Contract Manufacturing Market - UK
    • 9.4.5.1. UK: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.4.5.2. UK: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.4.5.3. UK: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.4.5.4. UK: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.4.6. Antibody Contract Manufacturing Market - France
    • 9.4.6.1. France: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.4.6.2. France: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.4.6.3. France: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.4.6.4. France: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.4.7. Antibody Contract Manufacturing Market - Germany
    • 9.4.7.1. Germany: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.4.7.2. Germany: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.4.7.3. Germany: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.4.7.4. Germany: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.4.8. Antibody Contract Manufacturing Market - Italy
    • 9.4.8.1. Italy: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.4.8.2. Italy: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.4.8.3. Italy: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.4.8.4. Italy: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.4.9. Antibody Contract Manufacturing Market - Spain
    • 9.4.9.1. Spain: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.4.9.2. Spain: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.4.9.3. Spain: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.4.9.4. Spain: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.4.10. Antibody Contract Manufacturing Market - Netherlands
    • 9.4.10.1. Netherlands: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.4.10.2. Netherlands: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.4.10.3. Netherlands: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.4.10.4. Netherlands: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.4.11. Antibody Contract Manufacturing Market - Russia
    • 9.4.11.1. Russia: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.4.11.2. Russia: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.4.11.3. Russia: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.4.11.4. Russia: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.4.12. Antibody Contract Manufacturing Market - Rest of Europe
    • 9.4.12.1. Rest of Europe: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.4.12.2. Rest of Europe: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.4.12.3. Rest of Europe: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.4.12.4. Rest of Europe: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• 9.5. Antibody Contract Manufacturing Market - Asia Pacific
  • 9.5.1. Asia Pacific: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
  • 9.5.2. Asia Pacific: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
  • 9.5.3. Asia Pacific: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
  • 9.5.4. Asia Pacific: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.5.5. Antibody Contract Manufacturing Market - China
    • 9.5.5.1. China: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.5.5.2. China: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.5.5.3. China: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.5.5.4. China: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.5.6. Antibody Contract Manufacturing Market - India
    • 9.5.6.1. India: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.5.6.2. India: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.5.6.3. India: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.5.6.4. India: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.5.7. Antibody Contract Manufacturing Market - Malaysia
    • 9.5.7.1. Malaysia: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.5.7.2. Malaysia: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.5.7.3. Malaysia: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.5.7.4. Malaysia: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.5.8. Antibody Contract Manufacturing Market - Japan
    • 9.5.8.1. Japan: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.5.8.2. Japan: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.5.8.3. Japan: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.5.8.4. Japan: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.5.9. Antibody Contract Manufacturing Market - Indonesia
    • 9.5.9.1. Indonesia: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.5.9.2. Indonesia: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.5.9.3. Indonesia: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.5.9.4. Indonesia: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.5.10. Antibody Contract Manufacturing Market - South Korea
    • 9.5.10.1. South Korea: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.5.10.2. South Korea: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.5.10.3. South Korea: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.5.10.4. South Korea: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.5.11. Antibody Contract Manufacturing Market - Australia
    • 9.5.11.1. Australia: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.5.11.2. Australia: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.5.11.3. Australia: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.5.11.4. Australia: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.5.12. Antibody Contract Manufacturing Market - Rest of Asia Pacific
    • 9.5.12.1. Rest of Asia Pacific: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.5.12.2. Rest of Asia Pacific: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.5.12.3. Rest of Asia Pacific: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.5.12.4. Rest of Asia Pacific: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• 9.6. Antibody Contract Manufacturing Market - Middle East & Africa
  • 9.6.1. Middle East & Africa: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
  • 9.6.2. Middle East & Africa: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
  • 9.6.3. Middle East & Africa: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
  • 9.6.4. Middle East & Africa: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.6.5. Antibody Contract Manufacturing Market - Saudi Arabia
    • 9.6.5.1. Saudi Arabia: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.6.5.2. Saudi Arabia: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.6.5.3. Saudi Arabia: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.6.5.4. Saudi Arabia: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.6.6. Antibody Contract Manufacturing Market - UAE
    • 9.6.6.1. UAE: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.6.6.2. UAE: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.6.6.3. UAE: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.6.6.4. UAE: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.6.7. Antibody Contract Manufacturing Market - Israel
    • 9.6.7.1. Israel: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.6.7.2. Israel: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.6.7.3. Israel: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.6.7.4. Israel: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.6.8. Antibody Contract Manufacturing Market - South Africa
    • 9.6.8.1. South Africa: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.6.8.2. South Africa: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.6.8.3. South Africa: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.6.8.4. South Africa: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.6.9. Antibody Contract Manufacturing Market - Rest of Middle East & Africa
    • 9.6.9.1. Rest of Middle East & Africa: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.6.9.2. Rest of Middle East & Africa: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.6.9.3. Rest of Middle East & Africa: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.6.9.4. Rest of Middle East & Africa: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
• 9.7. Antibody Contract Manufacturing Market - Latin America
  • 9.7.1. Latin America: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
  • 9.7.2. Latin America: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
  • 9.7.3. Latin America: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
  • 9.7.4. Latin America: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.7.5. Antibody Contract Manufacturing Market - Mexico
    • 9.7.5.1. Mexico: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.7.5.2. Mexico: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.7.5.3. Mexico: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.7.5.4. Mexico: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.7.6. Antibody Contract Manufacturing Market - Brazil
    • 9.7.6.1. Brazil: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.7.6.2. Brazil: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.7.6.3. Brazil: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.7.6.4. Brazil: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.7.7. Antibody Contract Manufacturing Market - Argentina
    • 9.7.7.1. Argentina: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.7.7.2. Argentina: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.7.7.3. Argentina: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.7.7.4. Argentina: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)
  • 9.7.8. Antibody Contract Manufacturing Market - Rest of Latin America
    • 9.7.8.1. Rest of Latin America: Antibody Contract Manufacturing Market, by Product, 2020-2034 (USD Billion)
    • 9.7.8.2. Rest of Latin America: Antibody Contract Manufacturing Market, by Source, 2020-2034 (USD Billion)
    • 9.7.8.3. Rest of Latin America: Antibody Contract Manufacturing Market, by Therapeutic Area, 2020-2034 (USD Billion)
    • 9.7.8.4. Rest of Latin America: Antibody Contract Manufacturing Market, by End User, 2020-2034 (USD Billion)

10. Competitive Landscape

• 10.1. Expansion and Acquisition Analysis
  • 10.1.1. Expansion
  • 10.1.2. Acquisitions
• 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

• 11.1. AbbVie Inc.
  • 11.1.1. Company Overview
  • 11.1.2. Financial Performance
  • 11.1.3. Product Benchmarking
  • 11.1.4. Recent Development
• 11.2. Boehringer Ingelheim International GmbH
  • 11.2.1. Company Overview
  • 11.2.2. Financial Performance
  • 11.2.3. Product Benchmarking
  • 11.2.4. Recent Development
• 11.3. Catalent, Inc.
  • 11.3.1. Company Overview
  • 11.3.2. Financial Performance
  • 11.3.3. Product Benchmarking
  • 11.3.4. Recent Development
• 11.4. Charles River Laboratories
  • 11.4.1. Company Overview
  • 11.4.2. Financial Performance
  • 11.4.3. Product Benchmarking
  • 11.4.4. Recent Development
• 11.5. Fujifilm Diosynth Biotechnologies
  • 11.5.1. Company Overview
  • 11.5.2. Financial Performance
  • 11.5.3. Product Benchmarking
  • 11.5.4. Recent Development
• 11.6. Lonza Group AG
  • 11.6.1. Company Overview
  • 11.6.2. Financial Performance
  • 11.6.3. Product Benchmarking
  • 11.6.4. Recent Development
• 11.7. Lotte Biologics
  • 11.7.1. Company Overview
  • 11.7.2. Financial Performance
  • 11.7.3. Product Benchmarking
  • 11.7.4. Recent Development
• 11.8. Merck Group
  • 11.8.1. Company Overview
  • 11.8.2. Financial Performance
  • 11.8.3. Product Benchmarking
  • 11.8.4. Recent Development
• 11.9. Samsung Biologics
  • 11.9.1. Company Overview
  • 11.9.2. Financial Performance
  • 11.9.3. Product Benchmarking
  • 11.9.4. Recent Development
• 11.10. Shilpa Medicare Ltd.
  • 11.10.1. Company Overview
  • 11.10.2. Financial Performance
  • 11.10.3. Product Benchmarking
  • 11.10.4. Recent Development
• 11.11. Thermo Fisher Scientific Inc.
  • 11.11.1. Company Overview
  • 11.11.2. Financial Performance
  • 11.11.3. Product Benchmarking
  • 11.11.4. Recent Development
• 11.12. WuXi Biologics
  • 11.12.1. Company Overview
  • 11.12.2. Financial Performance
  • 11.12.3. Product Benchmarking
  • 11.12.4. Recent Development